Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030
Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Fragment-based Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of 8.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Fragment-based Drug Discovery market.
Report Scope
The report analyzes the Fragment-based Drug Discovery market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.
Key Insights:
Why You Should Buy This Report:
Key Questions Answered:
Report Features:
Some of the 44 companies featured in this Fragment-based Drug Discovery market report include:
This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:
Key Attributes:
For more information about this report visit https://www.researchandmarkets.com/r/wnygg0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.